Nippon India Nifty Pharma ETF
NAV
₹27.11
as of 21 Aug 2026
Nippon India Nifty Pharma ETF is an open-ended Other ETFs scheme from Nippon India Mutual Fund managing ₹1,691 crore (as of 31 Jul 2026). Its Direct-plan NAV is ₹27.11 as of 21 Aug 2026. The expense ratio is 0.18% a year. Managed by Jitendra Tolani. This page is factual data only — it carries no rating and no recommendation.
Key facts
- Expense ratio
- 0.18% / yr
- as of 30 Jun 2026
- Fund size
- ₹1,691 crore
- as of 31 Jul 2026
- SIP available
- No
- Launched
- 6 Jul 2021
- ISIN
- INF204KC1089
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from NYVO’s own NAV data.
Rebased to 100data to 20 Aug 2026Benchmark: NIFTY Pharma
Nippon India Nifty Pharma ETF
₹198
+98% on ₹100 over 5.0 yrs
Other ETFs average
₹166
+66% on ₹100 over 5.0 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | 7.79% | 6.36% | +1.43 |
| 6 months | 17.26% | 15.40% | +1.86 |
| 1 year | 20.67% | 15.64% | +5.03 |
| 3 years (CAGR) | 20.39% | 20.47% | -0.08 |
| 5 years (CAGR) | 14.58% | 14.27% | +0.31 |
Category average across 210 funds, as of 20 Aug 2026. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible — read that number first.
1-year holding periods
- Worst
- -11.8%
- Median
- 12.1%
- Best
- 60.8%
49 windows over the last 60 months, stepped monthly; 71% ended positive. Worst window began 1 Sept 2021. Windows overlap — this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 15.3%
- Median
- 20.4%
- Best
- 25.5%
25 windows over the last 60 months, stepped monthly; 100% ended positive. Worst window began 2 Aug 2021. Windows overlap — this is the range of past start dates, not a probability of anything.
Risk, measured
- Sharpe ratio (3Y)
- 0.91
- Sharpe ratio (5Y)
- 0.52
- Sortino ratio (3Y)
- 1.56 vs category 1.55
- Standard deviation (3Y)
- 15.98%
- Beta (3Y)
- 0.94
- Alpha (3Y)
- 0.14%
- Deepest fall (5Y)
- -18.05%
Distance below its own peak
Every dip below 0 is the fund trading under a previous high — how deep and for how long is what a drawdown feels like.
Deepest fall
-15.2%
Right now
-1.3% below peak
Ahead of its benchmark in 39% of months (window: 3y, monthly) — benchmark: NIFTY Pharma, name shown only.
Where the money actually is
Equity
99.8%
Cash
0.2%
Whole-portfolio split, as of 31 Jul 2026. The size split below covers only the equity slice of this.
What it owns
23 positions · top 10 = 79.0%
Market-cap mix (equity sleeve)
Large 47.6%Mid 45.5%Small 6.7%Other 0.2%
as of 31 Jul 2026
Holdings by sector
Healthcare(10 in top 10)99.8%
- Sun Pharmaceuticals Industries Ltd21.29%
- Divi's Laboratories Ltd10.34%
- Cipla Ltd8.37%
- Torrent Pharmaceuticals Ltd7.59%
- Laurus Labs Ltd7.14%
- Dr Reddy's Laboratories Ltd7.07%
- Lupin Ltd5.93%
- Aurobindo Pharma Ltd4.42%
- Alkem Laboratories Ltd3.40%
- Glenmark Pharmaceuticals Ltd3.40%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 31 Jul 2026. Portfolio turnover 46.4% vs category 39.8% a year.
Money in, money out
- Net flow, 12 months
- +₹501 cr
- Net flow, 3 months
- +₹128 cr
as of 31 Jul 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of Nippon India Nifty Pharma ETF?
- ₹27.11 per unit as of 21 Aug 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of Nippon India Nifty Pharma ETF?
- 0.18% a year for the Direct plan, as of 30 Jun 2026.
- How large is Nippon India Nifty Pharma ETF?
- ₹1,691 crore under management as of 31 Jul 2026, in the Other ETFs category.
- How risky is Nippon India Nifty Pharma ETF?
- Its SEBI Riskometer reading is "Very High Risk".
- What are the 5-year returns of Nippon India Nifty Pharma ETF?
- 14.58% a year over the last 5 years (Direct plan, CAGR), against a Other ETFs average of 14.27%. Past returns do not predict future returns.
- What is the worst 3-year return of Nippon India Nifty Pharma ETF?
- 15.3% a year — the weakest of 25 overlapping 3-year holding periods, beginning 2 Aug 2021. The median was 20.4% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages Nippon India Nifty Pharma ETF?
- Jitendra Tolani, managing this fund for 1.5 years.
Where this fund sits
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund — growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Other ETFs funds
Data: NYVO research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (NIFTY Pharma) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.